Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Dow
Mallinckrodt
McKinsey
Harvard Business School

Last Updated: January 27, 2023

Details for Patent: 7,157,584


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Patent: 7,157,584
Title:Benzimidazole derivative and use thereof
Abstract:The present invention relates to a compound represented by the formula (I) ##STR00001## wherein R.sup.1 is a group represented by the formula ##STR00002## wherein R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are each independently a hydrogen atom or a C.sub.1-6 alkyl, or a salt thereof. The compound of the present invention is useful as an agent for the prophylaxis or treatment of circulatory diseases such as hypertension and the like and metabolic diseases such as diabetes and the like.
Inventor(s): Kuroita; Takanobu (Katano, JP), Sakamoto; Hiroki (Amagasaki, JP), Ojima; Mami (Amagasaki, JP)
Assignee: Takeda Pharmaceutical Company Limited (Osaka, JP)
Application Number:11/031,057
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,157,584
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent 7,157,584

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Azurity EDARBI azilsartan kamedoxomil TABLET;ORAL 200796-001 Feb 25, 2011 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Azurity EDARBI azilsartan kamedoxomil TABLET;ORAL 200796-002 Feb 25, 2011 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Azurity EDARBYCLOR azilsartan kamedoxomil; chlorthalidone TABLET;ORAL 202331-001 Dec 20, 2011 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Azurity EDARBYCLOR azilsartan kamedoxomil; chlorthalidone TABLET;ORAL 202331-002 Dec 20, 2011 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,157,584

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2004-048928Feb 25, 2004

International Family Members for US Patent 7,157,584

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 047972 See Plans and Pricing
Argentina 094588 See Plans and Pricing
Austria 370136 See Plans and Pricing
Austria 440095 See Plans and Pricing
Australia 2005214271 See Plans and Pricing
Brazil 122012009489 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Johnson and Johnson
McKinsey
Colorcon
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.